J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval
First-In-Class Approval In EU
With Darzalex and Carvykti already making J&J a leader in the field, the company has added another dimension to its offering with the first multiple myeloma bispecific antibody therapy.
